亚洲社会药学

本期目录

2017年, 第12卷, 第2期　刊出日期：2017-06-20 上一期    下一期

论文

Select

Application of SWOT Analysis and Porter’s Five Forces Analysis to State-owned Enterprise Affiliated Hospitals in China Wang Tao, Wu Zhi’ang, Li Shuchuen 2017 (2):  41-49.  摘要 ( 1027 )   PDF(486KB) ( 1303 )   Objective To put forward strategic suggestions for state-owned enterprise affiliated hospitals (EAH) to deal with current and potential competition and threats in healthcare reforms in China. Methods Status of state-owned enterprise affiliated hospitals in healthcare system in China was analyzed, and future development strategies for EAH according to SWOT and Porter's five-force model analysis were raised. Results and Conclusion The number of personnel, service efficiency, asset size and annual income of EAH was in a weak position compared with the average level of the national hospitals and health sector affiliated hospitals. Therefore, it is proposed that EAH should improve the management, expand the financing channels, target on specific market segments and be consistent with the policy and reform of the healthcare system. 相关文章 | 计量指标

Select

Measures to Speed up Drug Review Process in Japan and Its Implications Shi Wenwen, Sun Lihua 2017 (2):  50-56.  摘要 ( 519 )   PDF(571KB) ( 2606 )   Objective To provide references for improving the efficiency of drug review process in China. Methods systematical analysis was conducted to study the background, measures and achievements of drug review in Japan. Results and Conclusion Japan managed to change the situation of “lag of drug listing” by increasing the number of working staffs, enhancing review training, optimizing review procedures, strengthening the management of electronic submission data and review process, and expanding the range of communication significantly. By the end of 2014, the standard review time had been reduced to 11.9 months, and priority review time had been reduced to 8.8 months. Therefore, the development and evaluation of innovative drugs can be accelerated by means of preevaluation, increasing the numbers of the working staffs. Besides, a detailed review schedule should be set up and the supervision of the review process must be strengthened so that review department has to abide by the strict time limit. The communication of review should be standardized and the communication quality and the review efficiency should be improved. 相关文章 | 计量指标

Select

Analysis of New Drug Registration for Biological Products from 2010 to 2015 in China Liu Dandan, Chen Yuwen 2017 (2):  57-63.  摘要 ( 406 )   PDF(652KB) ( 1021 )   Objective To study the situation of new drug registration for biological products from 2010 to 2015 in China. Methods Information of new drug registration for biological products from 2010 to 2015 in China was collected and classified and development trend was made from several aspects: the total number of new drug registration application, application types, drug types and registration classification. Results and Conclusion New drug research and development of biological products in China showed a trend of rapid growth. At the same time, the innovation level of new drug research and development of biological products was improved. China has made a great achievement in monoclonal antibody research and development. 相关文章 | 计量指标

Select

Problems of Fake Anti-malarial Drugs in Cambodia Tem Darina, Mao Ningying 2017 (2):  64-70.  摘要 ( 443 )   PDF(606KB) ( 729 )   Objective To discuss the influence of fake anti-malarial drugs on public health, and to put forward some suggestions on fighting against fake anti-malarial drugs in Cambodia. Methods Multiple methods were applied, including data from Department of Drug and Food (DDF), Ministry of Health (MOH) in Cambodia, sample documents from the internet, to examine the problems of fake anti-malarial drugs in Cambodia. Results and Conclusion Majority of victims are uneducated sections of society. Especially people living in rural areas are the biggest victims of fake anti-malarial drugs. Most of the fake anti-malarial drugs are imported from other countries. Therefore, manufacturers and governments should cooperate to fight against fake anti-malarial drugs. 相关文章 | 计量指标

Select

Management of Subjects in Phase I Clinical Trials for New Drug Qian Cuihong, Lian Guiyu 2017 (2):  71-73.  摘要 ( 382 )   PDF(376KB) ( 677 )   Objective To standardize management of subjects in phase I clinical trials, reduce the risks of trials and to ensure the quality of trials. Methods Risk management was used to analyze main links of management of subjects, and to find out the major risk points and factors. Results and Conclusion Poor compliance of subjects is a major risk factor. The compliance of subjects and the quality of clinical trials can be improved by standardizing management of subjects. 相关文章 | 计量指标

Select

Research on Economic Evaluation of Rare Diseases Li Tongtong, Zhang Fang 2017 (2):  74-80.  摘要 ( 372 )   PDF(531KB) ( 559 )   Objective To study the related literatures on rare diseases and to provide references for economic evaluation of rare diseases. Methods Related literatures on rare diseases which were published in the Springer, Web of Science, China National Knowledge Infrastructure, Wan Fang Database and VIP Database from January 2006 to September 2016 were retrieved. Results and Conclusion A total of 101 articles were searched out and after screening, 53 articles were used for the analysis. Four aspects were classified for the research，including cost-effectiveness, economic evaluation, budget analysis and socioeconomic impact of rare diseases. In the field of rare diseases research, cost-effectiveness and rare economic evaluation were the research hotpots. The number of budget analysis and socioeconomic impact research was few. Therefore, researchers should have a comprehensive study on various aspects of rare diseases research so that they can provide references for rare diseases policy making in different countries. 相关文章 | 计量指标

Select

Influence Factors on Psychological Empowerment of Pharmaceutical Sales Representatives Pan Shuang, Wu Zhi’ang 2017 (2):  81-87.  摘要 ( 428 )   PDF(504KB) ( 721 )   Objective To analyze and evaluate influence factors of psychological empowerment of pharmaceutical sales representatives systematically. Methods 100 pharmaceutical sales representatives were investigated through analytic hierarchy process and Matlab software was used to analyze weights of all factors that may influence psychological empowerment of pharmaceutical sales representatives so that suggestions were raised. Results and Conclusion Organizational environment plays an important role in psychological empowerment, personnel feature is in the second place, while job characteristic is in the last place. There are many factors impacting psychological empowerment and pharmaceutical sales representatives should improve the awareness of work value, autonomy and self-efficacy through various ways. Therefore, work quality and efficiency of pharmaceutical sales representatives can be enhanced by controlling factors that affect psychological empowerment, such as establishing related systems and providing humanistic care. 相关文章 | 计量指标